BioLife Solutions

Q2 FY2026 EarningsQ2 FY26 results were characterized by a top-line beat and a massive GAAP EPS surprise due to a one-time tax valuation allowance release. Revenue reached $28.5M (+21% YoY), slightly exceeding the $28.2M consensus, while GAAP EPS of $0.91 significantly outperformed the $0.03 expected. However, gross margin contracted to 64.2% (vs. 64.7% expected) due to unfavorable product mix. The announcement of a definitive merger agreement with Repligen at $11.25 cash plus stock remains the primary catalyst for the stock price regardless of fundamental variances.